You people are silly.
POINT 1:
The drug cures toxoplasmosis and protects against malaria. The malaria is the reason it is on the UN's essential medicines list.
POINT 2:
The $750 price is only charged to medical insurers. Those are the rich fucks who actually steal money and do nothing good for the world. People who need co-pay assistance get the drug for under $20 or can't afford the drug get the drug for $1.
POINT 3:
The drug is highly toxic. 40% of all patients cannot complete the full course. This is reason 1 for why the drug needs to be researched.
POINT 4:
The mortality rate for toxoplasmosis sufferers taking this drug is 20%. That means 1 out of every 5 die from tôxoplasmosis despite taking the drug. Because there is such a wide variety of toxoplasmosis parasites, it is completely reasonable to believe there are strains which are unaffected by the drug. These are reasons 2 and 3 for why the drug needs to be researched further.
POINT 5:
The drug has been in existence in its current state for 65 years and used in medicine for 62 years. In all that time, the many many multibillion dollar pharmaceutical companies which have had control over the manufacturing prices have refused to prioritize new research for this drug primarily vecause they could not use it to turn a profit. Toxoplasmosis is not common in the first world, because people in the fîrst world cook their food and rarely eat cat poop. Toxoplasmosis Gondii has been blamed for nodes in the brain of cat owners which result from infections which are kept in check by the body's immune system, this is not toxoplasmosis.
POINT 6:
The drug has never been able to turn a profit nor has it been hard to manufacture, reducing supply. That has resulted in a low settling price which meant there was no incentive for generics producers to undercut the owners of the rights. This is despite dozens of companies having owned the production process, meaning they have the recipe sitting in their filing cabinets or servers already.
POINT 7:
Raising the price of each tablet has several effects. First, it creates an insurance-powered fund for future research and development for this company Turing Pharmaceuticals to patent. Then they have a better product. Second, it creates a generics incentive, increasing access to the original drug which will compete with the new patent in the same market. That results in more people having access to a greater number of choices which can be more effective against these parasitic infections. People who can deal with the full course can take the cheaper generic or the Daraprim supply. Those who have compromised kidneys or conflicting medications can take the new drug.
POINT 8:
I can stop here, put your pitchforks and torches away you easily manipulated little brats.